Age Associated Memory Impairment & Mild Cognitive Impairment (MCI)
Dunbar GC, Kuchibhatla R, Lee G (2011). A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. Journal of Psychopharmacology. 25: 1020-1029.
Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J (2006). Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). Journal of Psychopharmacology. 21: 171-178.
Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED (2012). Nicotine Treatment of Mild Cognitive Impairment: A Six-Month Double-Blind Pilot Clinical Trial. Neurology 84: 91-101.
Nicholl CG, Lynch S, Kelly CA, White L, Simpson PM, Wesnes KA, Pitt BMN (1995). The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? International Journal of Geriatric Psychiatry. 10: 199-206.
Wesnes KA (2000). Predicting, assessing, differentiating and treating the dementias: experience in MCI and various dementias using the CDR computerised cognitive assessment system. In: B. Vellas & LJ Fitten (Eds) Research and practice in Alzheimer’s disease, Volume 3. Serdi, Paris, 59-65.
Wesnes KA, Simmons D, Rook M, Simpson PM (1987). A double blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. Human Psychopharmacology. 2: 159-169.
Wesnes KA, Ward T (2001). Treatment of age-associated memory impairment. Evidence-Based Dementia Practice: A Practical Guide to Diagnosis and Management (With Internet Updates). N. Qizilbash, L. Schneider, H. Chuiet al, Blackwell Science Publications: 639-653.